

Canakinumab for Atherosclerotic Cardiovascular Disease: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review of [TOPIC]. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER's report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER's website](#).

- Aetna, Inc.
- America's Health Insurance Plans
- American College of Cardiology
- Anthem, Inc.
- Cigna, Inc.
- The FH Foundation
- International Atherosclerosis Society
- Mended Hearts
- National Forum for Heart Disease and Stroke Prevention
- Novartis AG
- Premera Blue Cross
- Society for Heart Attack Prevention and Eradication
- Society for Vascular Medicine
- UnitedHealthcare Services, Inc.
- Women Heart